Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Sinopharm unit inches toward vaccine breakthrough

    By Liu Zhihua | China Daily | Updated: 2020-04-30 10:42
    Share
    Share - WeChat
    A CNBG employee performs tests on the company's COVID-19 vaccines under development at a research institute in Wuhan, capital of Hubei province, on April 11.[Photo/Xinhua]

    China has adopted five technological approaches to develop COVID-19 vaccines-inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza viruses as vectors.

    The country has now approved one recombinant adenovirus vector vaccine and three inactivated vaccines for clinical trials, while the quest for vaccines using other technical routes is also advancing rapidly.

    Apart from Sinopharm's two inactivated vaccine candidates, an inactivated vaccine developed by Beijing-based Sinovac Research and Development Co Ltd was approved on April 13 for clinical trials.

    The recombinant adenovirus vector-based vaccine candidate, developed by the Academy of Military Medical Sciences of the People's Liberation Army and Chinese firm CanSino Bio, officially entered phase-2 human trials on April 12 and became the world's first COVID-19 vaccine candidate to reach this stage of trials, said the World Health Organization.

    Despite there being no accurate statistics on the exact number of COVID-19 vaccine programs worldwide, the WHO said earlier this month that there were currently 70 vaccine candidates in development.

    Sinopharm, officially known as China National Pharmaceutical Group Co Ltd, China's largest pharmaceutical company with more than 1,500 subsidiaries, including six publicly listed entities, is developing vaccines using two different technological approaches: inactivated and recombinant protein vaccines.

    According to a recent report by SinoLink Securities, developing inactivated vaccines usually takes more time compared with newer technologies of nucleic acid and recombinant vaccines because the traditional method has strict R&D conditions including high biosafety standards.

    But once successfully synthesized, inactivated vaccines can be massively produced while it is often difficult to produce vaccines using new technologies on a large scale due to a lack of production capacity, the report said.

    Liu Jingzhen, chairman of Sinopharm, said the company has set aside a fund of 1 billion yuan ($141.33 million) to support the vaccines' R&D.

    CNBG's April 12 randomized, double-blind, placebo parallel-controlled human trials took place in Jiaozuo, Henan province.

    The design of the clinical studies is in full accordance with the requirements of national norms, including gradually increasing inoculation dosages and starting with middle-aged groups, said Sinopharm.

    As of Thursday, a total of 96 people in three age groups aged between 18 and 60 had been inoculated, and all were reported to be in good condition, the company said, adding that participants will continue to be under close observation to assess the vaccine's safety.

    The phase-2 study aims at not only testing the vaccine's safety, but also figuring out vaccination procedures, including how many doses and how much of each are required.

    The vaccine will also go through the third phase of clinical trials, which will mainly test efficacy and safety, said the company.

    It may take more than a year to finish all three phases of human trials to determine whether the vaccine is safe and effective in protecting people from COVID-19, the company said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    日韩精品久久无码人妻中文字幕 | 精品无人区无码乱码毛片国产| 中文毛片无遮挡高潮免费| 精品国产一区二区三区无码| av无码久久久久不卡免费网站| 亚洲韩国—中文字幕| 国精品无码一区二区三区在线 | 无码国产午夜福利片在线观看| 中文一国产一无码一日韩| 欧洲精品久久久av无码电影| 久久无码AV中文出轨人妻| 亚洲中文字幕无码专区| 人妻丰满av无码中文字幕| 亚洲中文字幕无码中文字在线| 中文字幕在线视频播放| 中文字幕VA一区二区三区| 免费无码毛片一区二区APP| 国产精品99久久久精品无码| 最好看最新的中文字幕免费| 中文字幕在线无码一区二区三区| 午夜无码伦费影视在线观看| 亚洲中文无韩国r级电影| 天堂新版8中文在线8| 在线天堂中文WWW官网| 国产在线精品无码二区| 小13箩利洗澡无码视频网站| 国产成人无码区免费内射一片色欲 | 国产日韩AV免费无码一区二区| 亚洲日本va中文字幕久久| 亚洲综合最新无码专区| 色情无码WWW视频无码区小黄鸭| 日本精品中文字幕| 亚洲VA中文字幕不卡无码| 天堂√中文最新版在线| 五月婷婷无码观看| 久久久久亚洲av成人无码电影| 久久久久亚洲精品无码蜜桃| 久久人妻少妇嫩草AV无码专区 | 亚洲Aⅴ无码一区二区二三区软件| 国产Av激情久久无码天堂| 国产成人无码精品久久久久免费|